IYH:NYE-iShares U.S. Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 60.99

Change

-1.00 (-1.61)%

Market Cap

N/A

Volume

0.62M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-14 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-2.31 (-1.57%)

USD 40.46B
FHLC Fidelity® MSCI Health Care In..

-1.17 (-1.67%)

USD 2.91B
FXH First Trust Health Care AlphaD..

-2.16 (-1.94%)

USD 1.19B
XHE SPDR® S&P Health Care Equipme..

-1.78 (-1.96%)

USD 0.22B
IDNA iShares Genomics Immunology an..

-0.66 (-2.70%)

USD 0.15B
SBIO ALPS Medical Breakthroughs ETF

-1.18 (-2.93%)

USD 0.13B
XHS SPDR® S&P Health Care Service..

-2.68 (-2.80%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.79 (-2.68%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

-1.78 (-2.73%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.93 (-3.17%)

USD 0.01B

ETFs Containing IYH

RXD ProShares UltraShort Heal.. 10.32 % 0.77 %

+0.36 (+3.42%)

N/A
RXD ProShares UltraShort Heal.. 10.32 % 0.95 %

+0.36 (+3.42%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.54% 57% F 49% F
Dividend Return 0.92% 69% C- 15% F
Total Return 7.46% 52% F 42% F
Trailing 12 Months  
Capital Gain 13.59% 24% F 51% F
Dividend Return 1.31% 61% D- 15% F
Total Return 14.90% 24% F 45% F
Trailing 5 Years  
Capital Gain 49.03% 95% A 70% C-
Dividend Return 7.55% 72% C 20% F
Total Return 56.59% 90% A- 67% D+
Average Annual (5 Year Horizon)  
Capital Gain 6.81% 71% C- 58% F
Dividend Return 7.80% 76% C+ 54% F
Total Return 0.99% 79% B- 23% F
Risk Return Profile  
Volatility (Standard Deviation) 18.17% 57% F 60% D-
Risk Adjusted Return 42.93% 71% C- 60% D-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike